Abstract
Synthesis, characterization and investigation of antibacterial and antifungal activities of twelve camphor based 2,4-disubstituted 1,3-thiazoles is presented. Their structures were determined using NMR, IR, FAB MS and HRMS analyses. Among the derivatives, 3i and 5 were found to exhibit antifungal and antibacterial activities comparable to that of fluconazole and ciprofloxacin against yeast belonging to Candida spp., MIC 0.12-0.98 μg/ml and Gram-positive bacteria including both pathogenic S. aureus and opportunistic S. epidermidis, MIC 0.98-7.81 μg/ml, B. subtilis and B. cereus, MIC 3.91-31.25 μg/ml, and M. luteus, MIC 0.98 μg/ml species, respectively. Molecular docking studies of all compounds into the active sites of microbial enzymes indicated a possible targets SAP and NMT, thiazoles 3a-j, 4, 5 showed more favourable affinity than the native ligand.
Keywords: Antifungal drugs, gram-positive bacteria, molecular modelling, thiazoles, terpenes, thiosemicarbazones.
Graphical Abstract
Medicinal Chemistry
Title:Synthesis, In Vitro Biological Screening and Molecular Docking Studies of Novel Camphor-Based Thiazoles
Volume: 10 Issue: 6
Author(s): Krzysztof Z. Laczkowski, Konrad Misiura, Anna Biernasiuk, Anna Malm, Agata Siwek, Tomasz Plech, Emilia Ciok-Pater, Krzysztof Skowron and Eugenia Gospodarek
Affiliation:
Keywords: Antifungal drugs, gram-positive bacteria, molecular modelling, thiazoles, terpenes, thiosemicarbazones.
Abstract: Synthesis, characterization and investigation of antibacterial and antifungal activities of twelve camphor based 2,4-disubstituted 1,3-thiazoles is presented. Their structures were determined using NMR, IR, FAB MS and HRMS analyses. Among the derivatives, 3i and 5 were found to exhibit antifungal and antibacterial activities comparable to that of fluconazole and ciprofloxacin against yeast belonging to Candida spp., MIC 0.12-0.98 μg/ml and Gram-positive bacteria including both pathogenic S. aureus and opportunistic S. epidermidis, MIC 0.98-7.81 μg/ml, B. subtilis and B. cereus, MIC 3.91-31.25 μg/ml, and M. luteus, MIC 0.98 μg/ml species, respectively. Molecular docking studies of all compounds into the active sites of microbial enzymes indicated a possible targets SAP and NMT, thiazoles 3a-j, 4, 5 showed more favourable affinity than the native ligand.
Export Options
About this article
Cite this article as:
Laczkowski Z. Krzysztof, Misiura Konrad, Biernasiuk Anna, Malm Anna, Siwek Agata, Plech Tomasz, Ciok-Pater Emilia, Skowron Krzysztof and Gospodarek Eugenia, Synthesis, In Vitro Biological Screening and Molecular Docking Studies of Novel Camphor-Based Thiazoles, Medicinal Chemistry 2014; 10 (6) . https://dx.doi.org/10.2174/15734064113096660054
DOI https://dx.doi.org/10.2174/15734064113096660054 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets The Role of MicroRNA in Pathogenesis and as Markers of HCV Chronic Infection
Current Drug Targets Effects of Natural Products on Mcl-1 Expression and Function
Current Medicinal Chemistry Induction and Escalation Therapies in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Making Sense of Molecular Signatures in The Immune System
Combinatorial Chemistry & High Throughput Screening Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry New Purine Nucleoside Analogs for Acute Lymphoblastic Leukemia
Clinical Cancer Drugs The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets CB 1954: From the Walker Tumor to NQO2 and VDEPT
Current Pharmaceutical Design Advances and Challenges in the Synthesis of Highly Oxidised Natural Phenols with Antiviral, Antioxidant and Cytotoxic Activities
Current Medicinal Chemistry VEGF Signaling in Cancer Treatment
Current Pharmaceutical Design From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Receptor-Specific Peptides for Targeting of Liposomal, Polymeric, and Dendrimeric Nanoparticles in Cancer Diagnosis and Therapy
Current Molecular Imaging (Discontinued) Current Approaches in Antiviral Drug Discovery Against the Flaviviridae Family
Current Pharmaceutical Design Chemical Advances in Therapeutic Application of Exosomes and Liposomes
Current Medicinal Chemistry Nano-Chitosan Particles in Anticancer Drug Delivery: An Up-to-Date Review
Mini-Reviews in Medicinal Chemistry Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets Recent Advances in Radiation Therapy of Cancer Cells: A Step towards an Experimental and Systems Biology Framework
Current Radiopharmaceuticals Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase
Recent Patents on Anti-Cancer Drug Discovery